The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Lamisil 250 mg Tablets



Novartis Ireland LimitedPA0896/015/001

Main Information

Trade NameLamisil 250 mg Tablets
Active SubstancesTerbinafine
Dosage FormTablet
Licence HolderNovartis Ireland Limited
Licence NumberPA0896/015/001

Group Information

ATC CodeD01BA Antifungals for systemic use
D01BA02 terbinafine

Status

License statusAuthorised
Licence Issued12/12/1994
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back